Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Viral Vector Manufacturing Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The viral vector manufacturing market has experienced swift expansion in the past several years. Its value is projected to increase from $8.26 billion in 2025 to $9.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.9%. This historical growth has been driven by factors such as constrained manufacturing capabilities, elevated production expenses, dependence on conventional gene delivery techniques, regulatory obstacles, and supply chains that are not well-integrated.
The market for viral vector manufacturing is projected to experience rapid expansion over the coming years, with an anticipated value of $21.31 billion by 2030, reflecting a compound annual growth rate (CAGR) of 21.1%. This forecasted growth is driven by several key factors, including the increasing demand for gene and cell therapies, technological progress in viral vector development, heightened investment in research and development, the growth of contract manufacturing organizations, and a rising emphasis on personalized medicine. Significant developments shaping the market during this period include innovations in gene therapy, improvements in viral vector safety, the implementation of scalable production methods, enhancements in regulatory compliance, and progress in both upstream and downstream processing techniques.
Download A Free Sample Report For Comprehensive Market Insights:
#Viral Vector Manufacturing Market Growth Factors: Which Forces Are Supporting Market Expansion?
The rising occurrence of cancer and infectious diseases is anticipated to drive expansion in the viral vector manufacturing market in the coming years. An infectious disease is caused by a virus or its toxic byproducts, spreading to a susceptible host through contact with infected individuals, animals, or objects, while cancer encompasses a broad category of conditions where abnormal cells grow uncontrollably, invade neighboring tissues, and metastasize to other organs. Viral vectors are utilized to produce tumor antigens, which are proteins found on tumor cells, and these trigger the body’s anti-cancer immune response. In both preclinical and clinical studies, viral vectors have been employed as vaccines against a variety of infectious diseases. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that the number of diagnosed cancer cases in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a significant annual increase, which underscores the growing burden of cancer in the country. Additionally, in August 2024, data from the UK Health Security Agency, an executive agency in the UK, showed 368 measles cases in England in 2023, a nearly sevenfold jump from the 53 cases recorded in 2022, with the West Midlands and London contributing 44% and 33% of cases, respectively. Consequently, the growing prevalence of both cancer and infectious diseases is fueling the growth of the viral vector manufacturing market.
Viral Vector Manufacturing Market Segment Outlook: Which Categories Are Expanding The Fastest?
The viral vector manufacturing market covered in this report is segmented –
1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types
2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research
5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Other End Users
Subsegments:
1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26
2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others
3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others
4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others
5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others
Viral Vector Manufacturing Market Industry Trends: What Changes Are Reshaping Demand?
Key players in the viral vector manufacturing market are increasingly prioritizing the creation of cutting-edge solutions, particularly viral vector platforms tailored for production and manufacturing processes. These platforms constitute integrated systems optimized for the effective generation and handling of viral vectors, which are essential for gene therapy and vaccine development. A notable example occurred in May 2023 when AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), unveiled the BravoAAV and ProntoLVV platforms. These systems are engineered to provide adaptable and rapid vector development and manufacturing for cell and gene therapy programs, achieving GMP product delivery within nine months, leveraging a worldwide regulatory and supply infrastructure along with in-house plasmid DNA services. By incorporating customized processes, templated material strategies, and prequalified analytical techniques, these platforms play a pivotal role in the projected expansion of the viral vector manufacturing market to $5.5 billion by 2035, as they address the growing need for efficient production and delivery of impactful gene therapies and vaccines.
Viral Vector Manufacturing Market Key Companies And Competitive Benchmarking
Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV
Access The Complete Viral Vector Manufacturing Market Report:
Viral Vector Manufacturing Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the viral vector manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model